BioCentury
ARTICLE | Financial News

With anti-VEGF challenger in clinic, Kodiak files for IPO

September 10, 2018 2:07 AM UTC

Ophthalmic company Kodiak Sciences Inc. (Palo Alto, Calif.) filed to raise $100 million in an IPO on NASDAQ underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Chardan.

Using its antibody biopolymer conjugate (ABC) platform, Kodiak is developing therapies for retinal diseases. The company's lead program, KSI-301, consists of an anti-VEGF mAb designed to be pharmacologically similar to Lucentis ranibizumab, conjugated to a biopolymer intended to augment the therapy's stability and residence time in the eye...

BCIQ Company Profiles

Kodiak Sciences Inc.